Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | JAK1 | P23458 | 3/20 | 0.37 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.35 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP1 | P63208 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 5/20 | 0.33 |
| ▸ | ACACA | Q13085 | 4/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | EEF2K | O00418 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620967 | 1.00 | JAK2 (0.37) | JAK2JAK1DDR1CKS1BSKP1 | |
| SCHEMBL3615396 | 0.92 | JAK2 (0.32) | JAK2JAK1BRD4 | |
| SCHEMBL3609957 | 0.88 | KCNA3 (0.36) | JAK2JAK1CKS1BSKP1SKP2 | |
| SCHEMBL3615008 | 0.88 | KCNA3 (0.36) | JAK2JAK1CKS1BSKP1SKP2 | |
| SCHEMBL3611471 | 0.87 | RET (0.35) | JAK2JAK1SLC2A1 | |
| SCHEMBL3606693 | 0.87 | RET (0.35) | JAK2JAK1SLC2A1 | |
| SCHEMBL3618787 | 0.80 | KCNA3 (0.36) | JAK2JAK1DDR1CKS1BSKP1 | |
| SCHEMBL3611264 | 0.79 | KCNA3 (0.38) | JAK2JAK1DRD2 | |
| SCHEMBL3618320 | 0.76 | KCNH2 (0.34) | — | |
| SCHEMBL3611048 | 0.76 | KCNH2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | NRDC, NDC1, NANS | JAK2 4263/4885JAK1 4487/4885DDR1 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.